跳至主要内容
临床试验/CTRI/2024/03/064041
CTRI/2024/03/064041尚未招募4 期

Efficacy and safety of mesotheraphy with dutasteride in androgenic alopecia - NI

CUTIS Academy of Cutaneous Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age abve 18 years – 55 years.
  • Newly diagnosed cases of androgenetic alopecia.
  • Naive cases of AGA and non-responders of topical minoxidil.
  • Baseline serum DHT level within normal range.
  • Females of child-bearing potential agree to use a reliable method of birth control or remain absent during the study
  • Post menopausal females.
  • All other treatments for androgenetic alopecia are prohibited during the course of the study

排除标准

  • Patients using the following medications: inhibitors of CYP3A4 (verapamil) or drugs with antiandrogen effect (finasteride) in the last six months.
  • Patients suffering from ejaculatory or erectile dysfunction.
  • Pregnant & breast-feeding females

研究者

相似试验